Show simple item record

dc.contributor.authorDang, N
dc.contributor.authorOgura, M
dc.contributor.authorCastaigne, S
dc.contributor.authorFayad, L
dc.contributor.authorJerkeman, M
dc.contributor.authorRadford, John A
dc.contributor.authorPezzutto, A
dc.contributor.authorBondarenko, I
dc.contributor.authorStewart, D
dc.contributor.authorShnaidman, M
dc.contributor.authorSullivan, S
dc.contributor.authorVandendries, E
dc.contributor.authorTobinai, K
dc.contributor.authorRamchandren, R
dc.contributor.authorHamlin, P
dc.contributor.authorGiné, E
dc.contributor.authorAndo, K
dc.date.accessioned2017-08-15T09:24:50Z
dc.date.available2017-08-15T09:24:50Z
dc.date.issued2017-07-05
dc.identifier.citationRandomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 2017 Br J Haematolen
dc.identifier.issn1365-2141
dc.identifier.pmid28677896
dc.identifier.doi10.1111/bjh.14820
dc.identifier.urihttp://hdl.handle.net/10541/620495
dc.descriptionLymphoma Research Teamen
dc.language.isoenen
dc.rightsArchived with thanks to British journal of haematologyen
dc.titleRandomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.en
dc.typeArticleen
dc.contributor.departmentUniversity of Florida, Gainesville, FL, USANagoya Daini Red Cross Hospital, Nagoya, Japanen
dc.identifier.journalBritish Journal of Haematologyen


This item appears in the following Collection(s)

Show simple item record